USPH closes $76.5M acquisition of 50% interest in Metro, 50-clinic operator

U S PHYSICAL THERAPY INC /NV

Paid ~$76.5M: $75M cash plus 18,358 shares of USPH common stock.
Metro-managed clinics generate ~$64M annual revenue and ~$12M annual EBITDA.
Earnout provision allows up to $20M additional if performance targets are met.
Board expanded to 8; Michael G. Mayrsohn (Metro CEO) appointed as director.
Clinics primarily in New York, with plans for further expansion in NY and adjacent states.

item 3.02 item 8.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael G. Mayrsohn

director

USPH · U S PHYSICAL THERAPY INC /NV

Effective: 2025-02-24
Filed: November 1, 2024, 7:59 PM ET

In connection with the transactions contemplated by the Purchase Agreement, and effective as of February 24, 2025, the Company expanded its board of directors (the “Board”) from seven to eight directors and appointed Michael G. Mayrsohn as a director of the Company to fill such vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael G. Mayrsohn was appointed as director at U S PHYSICAL THERAPY INC /NV.

Action: appointed
Role: director

Exact text from the filing

In connection with the transactions contemplated by the Purchase Agreement, and effective as of February 24, 2025, the Company expanded its board of directors (the “Board”) from seven to eight directors and appointed Michael G. Mayrsohn as a director of the Company to fill such vacancy.

View on SEC.gov

U S PHYSICAL THERAPY INC /NV filing history →

Source: SEC EDGAR

accession 0000885978-24-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.